Sunday, 2 October, 2022

Topic: Cipla

Drugmaker Cipla eyes acquisitions in India, US after Covid windfall

Cipla says it's open to mergers & acquisitions. It may partner with smaller firms working on mRNA platforms after the technology came to the fore during the pandemic.

Cipla gets DCGI nod to import Moderna’s Covid vaccine for restricted emergency use in India

Permission for restricted emergency use potentially opens up a clear possibility of this vaccine being imported to India in the near future, said NITI Aayog Member Dr V K Paul.

Roche India gets nod for emergency use of Casirivimab, Imdevimab for Covid treatment

The antibody cocktail is to be used for the treatment of mild to moderate Covid in adults and pediatric patients with a high risk of severe symptoms, Roche said in a statement.

Only boycott of British goods won’t do — Why Abdul Hamied went on to create Cipla

In 'Caring For Life: The Cipla Story Since 1935', Tulsi Vatsal writes about how Khwaja Abdul Hamied wanted to create a science-based industry for India.

Cipla to experiment with Covid drug remdesivir composition to reduce effect on kidneys

Government's subject expert committee asks Cipla to assess renal toxicity of remdesivir's new formulation through a bioequivalence study as well as clinical trials.

India could be producing over 20,000 vials of Remdesivir per day by month-end: Govt data

Remdesivir is now being manufactured by Cipla, Hetero Labs and Mylan. Cipla Wednesday launched the drug under the brand name Cipremi.

Govt asks pharma firms when remdesivir, the big hope against Covid, can be made in India

Drug has shown benefits in reducing recovery time for some patients, and the govt has asked companies if they’re in touch with Gilead Sciences for a licence.

Indian drugmakers begin developing remdesivir, ‘world’s best shot’ against Covid-19

In a trial involving monkeys, early treatment of Covid-19 with remdesivir has shown to reduce symptoms of the disease and lung damage. 

Bigotry over Tablighi Jamaat is a familiar pattern. All Muslims will be blamed for acts of few

Heroic acts of Azim Premji or Shah Rukh Khan do not bring credit to the community. But the blame for the ignorance of Tablighi Jamaat members must be shared by all Muslims.

Cipla pacifies chemists’ lobby, says ‘no plans’ to partner Medlife

Facing a boycott threat by over 8.5 lakh chemists, Cipla tells lobby that it values the role of offline chemists.

On Camera


Illustration by Prajna Ghosh | ThePrint

Over 38% inmates in Indian jails are OBCs, 10% increase in a decade, study finds

Religious minorities, specifically Muslims and Sikhs, have been overrepresented among prison inmates for years now, but there have been some shifts in the last decade, NCRB data shows.
A man counts Indian currency notes inside a shop in Mumbai, India | Reuters/Francis Mascarenhas

RBI tells state refiners to reduce dollar buying in spot market, contain sharp fall in rupee

RBI has ensured that $9 billion has been made available at overseas branches of some Indian banks for the country's three state-run refiners to tap, according to sources.


Naval Group & IIT Goa signing agreement to extend partnership on 28 September | Twitter @navalgroup

France’s Naval Group, IIT Goa extend R&D deal for underwater surveillance, submarine imaging

Agreement will act as catalyst for improving analysis of data collected by underwater sensors through application of neural systems & AI.

India’s hijab supporters will lose even if they win SC battle. Because the real war is political

In a highly polarised time, cornered minorities tend to lean back and protect the roots and fundamentals of what is so dear to them. Politically, it can often be a bad trap.